Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Related JAZZ
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA

 

Related Articles (JAZZ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters